GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005122222 | Liver | HCC | positive regulation of protein transport | 194/7958 | 303/18723 | 2.41e-14 | 1.56e-12 | 194 |
GO:000690021 | Liver | HCC | vesicle budding from membrane | 53/7958 | 61/18723 | 7.38e-13 | 3.80e-11 | 53 |
GO:009719122 | Liver | HCC | extrinsic apoptotic signaling pathway | 143/7958 | 219/18723 | 6.99e-12 | 2.97e-10 | 143 |
GO:200123412 | Liver | HCC | negative regulation of apoptotic signaling pathway | 145/7958 | 224/18723 | 1.33e-11 | 5.36e-10 | 145 |
GO:005125822 | Liver | HCC | protein polymerization | 182/7958 | 297/18723 | 4.17e-11 | 1.58e-09 | 182 |
GO:002260422 | Liver | HCC | regulation of cell morphogenesis | 188/7958 | 309/18723 | 4.84e-11 | 1.82e-09 | 188 |
GO:005165621 | Liver | HCC | establishment of organelle localization | 226/7958 | 390/18723 | 4.15e-10 | 1.34e-08 | 226 |
GO:200123621 | Liver | HCC | regulation of extrinsic apoptotic signaling pathway | 98/7958 | 151/18723 | 2.17e-08 | 5.08e-07 | 98 |
GO:005165021 | Liver | HCC | establishment of vesicle localization | 103/7958 | 161/18723 | 2.94e-08 | 6.69e-07 | 103 |
GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
GO:001003822 | Liver | HCC | response to metal ion | 208/7958 | 373/18723 | 1.35e-07 | 2.56e-06 | 208 |
GO:00481991 | Liver | HCC | vesicle targeting, to, from or within Golgi | 20/7958 | 21/18723 | 4.57e-07 | 7.50e-06 | 20 |
GO:001076922 | Liver | HCC | regulation of cell morphogenesis involved in differentiation | 65/7958 | 96/18723 | 5.17e-07 | 8.37e-06 | 65 |
GO:000726521 | Liver | HCC | Ras protein signal transduction | 187/7958 | 337/18723 | 8.89e-07 | 1.35e-05 | 187 |
GO:005164821 | Liver | HCC | vesicle localization | 107/7958 | 177/18723 | 1.05e-06 | 1.57e-05 | 107 |
GO:190002422 | Liver | HCC | regulation of substrate adhesion-dependent cell spreading | 42/7958 | 57/18723 | 1.75e-06 | 2.45e-05 | 42 |
GO:000862511 | Liver | HCC | extrinsic apoptotic signaling pathway via death domain receptors | 55/7958 | 82/18723 | 5.97e-06 | 7.35e-05 | 55 |
GO:000690311 | Liver | HCC | vesicle targeting | 34/7958 | 45/18723 | 6.75e-06 | 8.08e-05 | 34 |
GO:00301932 | Liver | HCC | regulation of blood coagulation | 46/7958 | 66/18723 | 7.12e-06 | 8.47e-05 | 46 |
GO:001077022 | Liver | HCC | positive regulation of cell morphogenesis involved in differentiation | 53/7958 | 79/18723 | 8.69e-06 | 1.02e-04 | 53 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0517162 | Liver | Cyst | Coronavirus disease - COVID-19 | 75/339 | 232/8465 | 2.97e-49 | 4.27e-47 | 3.53e-47 | 75 |
hsa0517172 | Liver | Cyst | Coronavirus disease - COVID-19 | 75/339 | 232/8465 | 2.97e-49 | 4.27e-47 | 3.53e-47 | 75 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FGA | SNV | Missense_Mutation | | c.1663N>G | p.Thr555Ala | p.T555A | P02671 | protein_coding | tolerated(0.08) | benign(0.046) | TCGA-A2-A0SW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD |
FGA | SNV | Missense_Mutation | | c.1443N>C | p.Glu481Asp | p.E481D | P02671 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AR-A24L-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | PD |
FGA | SNV | Missense_Mutation | rs745321779 | c.878G>T | p.Gly293Val | p.G293V | P02671 | protein_coding | deleterious(0.01) | possibly_damaging(0.784) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
FGA | SNV | Missense_Mutation | | c.74N>T | p.Gly25Val | p.G25V | P02671 | protein_coding | deleterious(0.02) | possibly_damaging(0.861) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FGA | SNV | Missense_Mutation | | c.633N>A | p.Asp211Glu | p.D211E | P02671 | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
FGA | SNV | Missense_Mutation | novel | c.2422N>G | p.Trp808Gly | p.W808G | P02671 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
FGA | insertion | In_Frame_Ins | novel | c.1375_1376insAATTTACTAGTAGCACGAGTTACAACAGAGGAG | p.Arg459delinsGlnPheThrSerSerThrSerTyrAsnArgGlyGly | p.R459delinsQFTSSTSYNRGG | P02671 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
FGA | insertion | Nonsense_Mutation | novel | c.1980_1981insATCATTACATAAT | p.Val661IlefsTer4 | p.V661Ifs*4 | P02671 | protein_coding | | | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
FGA | insertion | Nonsense_Mutation | novel | c.1771_1772insTTCTTTCCTAAATATAAAT | p.Arg591IlefsTer4 | p.R591Ifs*4 | P02671 | protein_coding | | | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FGA | SNV | Missense_Mutation | | c.2245N>A | p.Glu749Lys | p.E749K | P02671 | protein_coding | deleterious(0.02) | benign(0.121) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | | RETEPLASE | RETEPLASE | |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | | RECOMBINANT FACTOR IX FC FUSION PROTEIN | | |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | | ALFIMEPRASE | ALFIMEPRASE | |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | | ANISTREPLASE | ANISTREPLASE | |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | inhibitor | CHEMBL1201505 | FIBRINOLYSIN, HUMAN | |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | | eptifibatide | EPTIFIBATIDE | 20938371 |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | | tirofiban | TIROFIBAN | 20938371 |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | | abciximab | ABCIXIMAB | 20938371 |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | | ALTEPLASE | ALTEPLASE | |